|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Dodatne storitve |
|
|
© 2024 SFX by Ex Libris Inc. | Politika piškotkov
CrossRef Omogočeno
|